eyeforpharma's 7th Annual Sales Force Effectiveness

eyeforpharmaeyeforpharma's 7th annual Sales Force Effectiveness, Princeton, May 4-5 2009 is borne out of ongoing in-depth research with hundreds of your peers. Seven VPs sit among a 30-strong speaker faculty to present on what we know are critical topics.

eyeforpharma is a leader in the Sales Force Effectiveness space worldwide and with nearly a decade of experience in this field, brings together elite audiences of leading industry executives to focus on the core issues.

Topics that will be covered:

  • SALES STRATEGY: Refocus your sales approach around your customer to succeed in a changing selling environment
  • TRAINING, DEVELOPMENT & LEADERSHIP: Examine innovative coaching models and develop your leadership ethos to ensure your sales force is continually evolving
  • SALES TOOLS AND TECHNOLOGY: Leverage your sales tools and data resources to streamline your technology
  • PHYSICIAN ACCESS: Connect directly with your customer. Engage with 5 key opinion leaders to ensure optimal communication and collaboration
  • A NEW COMMERCIAL MODEL: Evaluate what your company needs to achieve in a new model and hear practical techniques to ensure it expedites your sales objectives

For further information and registration, please visit:
http://www.eyeforpharma.com/sfeusa

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...